[HTML][HTML] Ebola virus disease

ST Jacob, I Crozier, WA Fischer, A Hewlett… - Nature reviews Disease …, 2020 - nature.com
Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus
(EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission …

[HTML][HTML] SARS-CoV-2 and coronavirus disease 2019: what we know so far

FA Rabi, MS Al Zoubi, GA Kasasbeh, DM Salameh… - Pathogens, 2020 - mdpi.com
In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They
were caused by a previously unknown coronavirus. All patients had been associated with …

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

L Li, W Zhang, Y Hu, X Tong, S Zheng, J Yang, Y Kong… - Jama, 2020 - jamanetwork.com
Importance Convalescent plasma is a potential therapeutic option for patients with
coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are …

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

C Shen, Z Wang, F Zhao, Y Yang, J Li, J Yuan, F Wang… - Jama, 2020 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) is a pandemic with no specific
therapeutic agents and substantial mortality. It is critical to find new treatments. Objective To …

[HTML][HTML] Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

RL Kruse - F1000Research, 2020 - ncbi.nlm.nih.gov
Abstract A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential
respiratory viral pandemic to the world population. Current efforts are focused on …

Convalescent plasma to treat COVID-19: possibilities and challenges

JD Roback, J Guarner - Jama, 2020 - jamanetwork.com
In this issue of JAMA, Shen et al report findings from a preliminary study of 5 severely ill
patients with coronavirus disease 2019 (COVID-19) who were treated in the Shenzhen Third …

[HTML][HTML] Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

G Zhou, Q Zhao - International Journal of Biological Sciences, 2020 - ncbi.nlm.nih.gov
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …

[HTML][HTML] COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection

K Lechowicz, S Drożdżal, F Machaj, J Rosik… - Journal of clinical …, 2020 - mdpi.com
In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of
symptoms, mainly respiratory infection. In March 2020, the World Health Organization …

[HTML][HTML] The convalescent sera option for containing COVID-19

A Casadevall, L Pirofski - The Journal of clinical …, 2020 - Am Soc Clin Investig
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as …

[HTML][HTML] Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19

RP Saha, AR Sharma, MK Singh, S Samanta… - Frontiers in …, 2020 - frontiersin.org
As the COVID-19 is still growing throughout the globe, a thorough investigation into the
specific immunopathology of SARS-CoV-2, its interaction with the host immune system and …